| Metric | Value ($ M) |
|---|---|
| Revenue | 10.00 |
| Total Income | 10.00 |
| Expenditure | 23.33 |
| PBT | — |
| Net Profit | -12.48 |
| OPM | — |
| NPM | — |
| EPS | -8.07 |
Evommune Reports Q3 2025 Financial Results
04 May 2026 · 4 May, 6:55 am
Summary
Evommune, Inc. announced its financial results for the third quarter ended September 30, 2025. The company reported revenue of $10.0 million, a significant increase from the same quarter in the previous year. Research and development expenses increased to $19.6 million. The company completed its IPO in November 2025, raising $172.5 million. Evommune anticipates Phase 2b data from the EVO756 CSU trial in the first half of 2026.
Key Highlights
- 1
Evommune reported revenue of $10.0 million for the third quarter ended September 30, 2025, compared to zero for the same period in 2024.
- 2
The company's research and development expenses were $19.6 million for the third quarter of 2025, compared to $13.3 million for the third quarter of 2024.
- 3
Evommune's general and administrative expenses were $3.7 million for the third quarter of 2025, compared to $3.2 million for the third quarter of 2024.
- 4
Net loss totaled $12.5 million for the third quarter of 2025, compared to $15.9 million for the third quarter of 2024.
- 5
The company completed its IPO in November 2025, raising gross proceeds of $172.5 million.
- 6
As of September 30, 2025, Evommune had cash, cash equivalents, and investments of $76.0 million, compared to $72.0 million as of December 31, 2024.
Management Comments
Luis Peña
“The recent completion of our IPO puts us in a strong position to deliver on the years ahead, with three Phase 2 readouts across our two lead programs, EVO756 and EVO301, expected next year. Atopic dermatitis (AD) remains the most prevalent autoimmune disease, and the need for more treatment options is urgent. We’re advancing two programs targeting novel mechanisms designed to give physicians and patients new tools to treat AD, if approved. MRGPRX2 antagonism is unique in its potential to change the paradigm as the first target that modulates both mast cells and sensory neurons, and IL‑18 inhibition has the potential to become a front-line biologic target in AD.” “We also anticipate reporting top-line Phase 2b data from the EVO756 CSU trial in the first half of 2026 and are optimistic that these data will support ongoing development in CSU, which continues to be underserved by existing treatment options and represents a significant market opportunity,”
Jeegar Patel
“Overall, we are energized by the progress and execution across our pipeline, which has broad potential for patients suffering from a range of chronic inflammatory diseases. By identifying and addressing critical gaps in the current treatment landscapes, our team is working diligently to continue to discover and add to the pipeline, with a goal of delivering therapies that provide rapid symptom relief and safe, durable resolution of underlying chronic inflammatory disease.”
Informational and educational content only. Not investment advice.